Slow release oral morphine (SROM) + Methadone
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid-Related Disorders
Conditions
Opioid-Related Disorders, Opiate Substitution Treatment, Morphine, Methadone, Fentanyl
Trial Timeline
Dec 6, 2019 → Jun 1, 2020
NCT ID
NCT03948464About Slow release oral morphine (SROM) + Methadone
Slow release oral morphine (SROM) + Methadone is a phase 3 stage product being developed by Mayne Pharma Group for Opioid-Related Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT03948464. Target conditions include Opioid-Related Disorders, Opiate Substitution Treatment, Morphine.
What happened to similar drugs?
2 of 2 similar drugs in Opioid-Related Disorders were approved
Approved (2) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03948464 | Phase 3 | Terminated |
Competing Products
2 competing products in Opioid-Related Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naltrexone for extended-release injectable suspension + Oral naltrexone | Alkermes | Approved | 40 |
| Naltrexone | Alkermes | Approved | 40 |